NCT03898622View on ClinicalTrials.gov

Supplementation of Thyroid Hormone for TSH Control in Patients With Chronic Kidney Disease Without TRR.

PHASE3CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

January 31, 2019

Study Completion Date

March 1, 2019

Conditions
Chronic Kidney DiseasesSubclinical Hypothyroidism
Interventions
DRUG

Levothyroxine

levothyroxine with a safe dose for our population with high cardiovascular risk of 0.25mcg so that the patient's weight range between 50-80kg maintains a dosage of 0.3-0.5mcg / kg / day that does not affect the thyroid axis) fasting levothyroxine (in the case of taking a drug that interacts with absorption, use of it is changed according to the specified hours, see Table 2), and adjusted according to TSH levels \> 1 and normal T4L

Trial Locations (1)

44280

Kidney health clinic, Civil Hospital of Guadalajara, Guadalajara

All Listed Sponsors
lead

Hospital Civil de Guadalajara

OTHER

NCT03898622 - Supplementation of Thyroid Hormone for TSH Control in Patients With Chronic Kidney Disease Without TRR. | Biotech Hunter | Biotech Hunter